Skip to main content
Premium Trial:

Request an Annual Quote

TriLink to Sell QuantiBact TINA Oligos Under Licensing Pact

Premium

TriLink Biotechnologies said today that it has inked a licensing agreement with Denmark's QuantiBact to offer twisted intercalating nucleic acid, or TINA, modified oligonucleotides.

TINA molecules are intercalators placed at the 5' end of primers to stabilize duplex formation, thus improving the sensitivity and specificity of endpoint and real-time PCR, TriLink said. The molecules may be used wherever an enhanced melting temperature is required such as triplex formation, or potentially even gene silencing, the company said.

QuantiBact scientists published a paper last year in PLoS One describing how adding ortho-TINA molecules at the 5' position to standard primers in a qPCR experiment enabled 100 percent efficiency in "significantly stressed reaction conditions," including lower primer concentrations and increased annealing temperatures (PCR Insider, 6/21/2012).

TriLink said it will make the modified oligos available in June.

"At TriLink we pride ourselves on our quality and our ability to handle unique nucleic acid modifications," TriLink President and CEO Richard Hogrefe said in a statement. "This makes us an ideal manufacturer of TINA oligos."

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.